companies / actithera-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 86,400,00086.4M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | Oslo | |
| industry | unknown | |
| stage | series-a |
Actithera develops cancer treatments that attach radioactive isotopes to designed molecules that deliver radiation precisely to tumors. It serves cancer patients through personalized radioligand therapy. Its proprietary chemistry matches radionuclide half-life to compound residence time for prolonged tumor retention with strong safety.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-07-01 | series-a | 70,200,00070.2M | null | ○ |
Nginx, WordPress, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.9, DoubleClick Floodlight, cdnjs, CookieYes, Python
| fact | status | src |
|---|---|---|
| Series A, $70.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |